The drug demonstrated an acceptable safety profile and objective responses were observed in non-Hodgkin's lymphoma patients and in solid tumour patients that were histologically negative for either of the SWI/SNF complex subunits INI1 or SMARCA4. Here, SMARCB1 is linked to non-Hodgkin lymphoma.